Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Cancer.
This Prospective, single-arm Phase Ⅱ study is to determine the efficacy and safety of Once-daily Simultaneous Modulated Accelerated Radiotherapy combined with S-1/DDP for geratic esophageal squamous cell carcinoma patients.
Esophageal Squamous Cell Carcinoma
RADIATION: SMART|DRUG: DDP|DRUG: S-1
Clinical response rate, the percentage of patients who had partial remission or complete remission after chemoradiotherapy, 2-year
progression-free survival, 3-year|overall survival, 3-year|grade 3 or 4 toxicities according to CTCAE4.0, the percentage of patients who develop grade 3 or 4 toxicities during and 1 year after radiochemotherapy, 1 year after radiochemotherapy
This Prospective, single-arm Phase Ⅱ study is to determine the efficacy and safety of Once-daily Simultaneous Modulated Accelerated Radiotherapy combined with S-1/DDP for geratic esophageal squamous cell carcinoma patients.